Master Manufacturing Services Agreement 14 JULY 2017Product Agreement • August 11th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • England
Patheon's liability for Active Materials calculated in accordance with Section 2.2 of the Master Agreement for any Product in a Year will not exceed, in the aggregate, the maximum credit value set forth below:
LICENSE AGREEMENTLicense Agreement • August 11th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • New York
This agreement (“Agreement”) is made by and between Recro Pharma, Inc., a Pennsylvania corporation having an address at 490 Lapp Road, Malvern PA 19355 (“Licensee”), and Cornell University (“University”) as represented by its Center for Technology Licensing (“CTL”) at Cornell University at 395 Pine Tree Road, Ithaca, NY 14850 (University, CTL and CRF (as defined below) collectively “Cornell” and each of Licensee and Cornell a “Party” and collectively, the “Parties”).
ContractAnd Supply Agreement • August 11th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations
[***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
PRODUCT AGREEMENT (Includes Schedules A to D) PRODUCT AGREEMENTProduct Agreement • August 11th, 2017 • Recro Pharma, Inc. • Pharmaceutical preparations • Dublin
This Product Agreement (this “Product Agreement”) is issued under the Master Manufacturing Services Agreement dated July 14th, 2017 between Patheon UK Limited and Recro Ireland Limited (the “Master Agreement”), and is entered into July 14th, 2017 (the “Effective Date”), between Patheon UK Limited, a corporation existing under the laws of England, having a principal place of business at Kingfisher Drive, Covingham, Swindon, SN3 5BZ, England (“Patheon”) and Recro Ireland Limited a private limited company incorporated in Ireland with registered number 562027, having its registered office at 25/28 North Wall, Dublin 1, (“Client”).
